
CLAIMS



1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,




(I)

wherein,


R_1 is -CH_2-cyclopropyl, and the -CH_2-cyclopropyl is optionally substituted by 1, 2 or 3 R_a;




R_2 is selected from  and , and the  and  are optionally substituted by 1, 2 or 3 R_b;

R_3-L_1- is ;

R_a is selected from F, Cl, Br and CH_3;


R_b is selected from F, Cl, Br, NH_2, COOH, CH_3, CF_3, OCH_3, -C(=O)-CH_3 and -NH-C(=O)NH-CH_3.


2. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein, R_1 is .

3. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein, R_2 is selected from ,  and .

4. A compound represented by the following formula or a pharmaceutically acceptable


salt thereof, wherein, the compound is selected from:






and .

5. The compound or the pharmaceutically acceptable salt thereof according to claim 4, wherein, the compound is selected from:



and



.

6. Use of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of a disease associated with kappa receptor agonists, wherein the disease associated with kappa receptor agonist is pain or pruritus.